

B) BRIEF PAPERS ON RESEARCH AND CLINICAL EXPERIMENTS

Progression of chronic kidney disease. Prevalence of anxiety and depression in autosomal dominant polycystic kidney disease

Nefrologia 2012;32(3):397-9

doi:10.3265/Nefrologia.pre2012.Feb.11379

To the Editor,

Autosomal dominant polycystic kidney disease (ADPKD) affects the physical condition of the patients and has an impact on mental health.¹ Anxiety and depression are the two most commonly associated psychological disorders with chronic kidney diseases (CKD).²

Depression is an affective disorder that is associated with a sense of loss that many patients experience when faced with renal failure, since they lose autonomy, their physical health deteriorates, and watch as their family and occupational roles are altered. Despite being the most common psychological problem among patients with CKD, depression has not been adequately studied in relation to the different stages of the disease.³

Anxiety, the second most commonly associated pathology with CKD, is a warning response produced by the body to situations of danger, threat, or change. However, when anxiety is maintained in the absence of danger, or cannot be coped with, it becomes pathological. This leads to behavioural changes⁴ in the patient that alter relationships with health professionals and the family, and can even lead to non-compliance with medical treatment.

In addition, suffering from one of these two psychological disorders in the initial stages of CKD is a predictor for elevated mortality in patients that reach later stages.⁵ Although technological

advancements have enabled us to reduce the mortality of patients with CKD, depression and anxiety increase the risk of suicide.⁶

The high prevalence of depression in patients with CKD is mediated by the combination of the physical symptoms of depression and the symptoms experienced by dialysis patients, which are the consequence of nephrological disease. Since this combination can lead to an over-estimation of the prevalence of this psychological problem in renal patients, we need to improve the precision and accuracy of the diagnostic process. One way to improve in this area is to use the Hospital Anxiety and Depression Scale (HADS),⁴ as we did in our study, as this does not take into account physical symptoms in the overall score for diagnosing depression, but only cognitive symptoms that are characteristic of this mood disorder.⁷

With this in mind, we examined the prevalence of anxiety and depression in patients with ADPKD. We also sought to determine whether clinical variables could be correlated with the specific symptoms characteristic of these two psychological disorders.⁸

The first objective of our study was to calculate the prevalence of anxiety and depression in patients with ADPKD (Table 1). The prevalence of these to psychological disorders in patients with ADPKD on haemodialysis (HD) was lower than in those without ADPKD that were undergoing the same treatment (55.9% of patients with depression and 46.72% of patients with anxiety). However, the estimated rates of depression in non-HD patients were

similar to those observed by Hedayati et al.⁹ We are unable to establish comparisons with the prevalence of anxiety in non-HD patients, since no studies have been carried out in this field.

Our second objective was to establish which specific symptoms of these two psychological disorders were associated with two clinical variables (time on HD and time since diagnosis). Our predictions were less exact in this subject, since no studies have specifically examined this topic.

A detailed analysis of questionnaire items and clinical variables, which specifically examined the relationship between HADS and HD/non-HD, time on HD, and time since the diagnosis, revealed several significant differences.

We observed that HD/non-HD influenced the feeling of lethargy and unrest and it appears that the duration of dialysis treatment plays an important role in several items (Table 2). As Watnick et al¹⁰ showed, symptoms of depression and anxiety are most common at the start of dialysis.

We also observed that scores for a feeling of lethargy (Table 2) were higher in patients that had spent 2.2-22 years on HD, as compared to those with only 0-4 months of treatment. Contrary to the aforementioned results regarding anxiety, the latter finding is supported by several studies that affirm those patients that have been on dialysis for more than one year have a greater tendency for depression.¹¹

Our results also suggest that the time since the patient was diagnosed with

Table 1. Scores for the hospital anxiety and depression questionnaire

| | Possible depression | Depression | Possible anxiety | Anxiety |
|-----------------------|---------------------|------------|------------------|-----------|
| Non-haemodialysis (%) | 5 (14.3%) | 1 (2.9%) | 6 (17.1%) | 3 (8.6%) |
| Haemodialysis (%) | 6 (25%) | 1 (4.2%) | 5 (20.8%) | 4 (16.7%) |

kidney disease is significantly correlated with feelings of concern and sudden panic (Table 2). In this manner, scores were higher among patients that had been diagnosed with ADPKD for 0-12 months than in those who had been diagnosed with ADPKD for 14-25 months. We believe that this finding confirms that concern regarding this disease is strongest immediately following diagnosis.

In conclusion, our study shows that patients with ADPKD have a higher prevalence of symptoms of anxiety and depression than in the general population,¹² regardless of whether or not they are undergoing dialysis treatment. More studies are necessary that examine psychological aspects of patients with ADPKD in order to attend to their biopsychosocial needs in the best possible manner. An early identification of psychological problems along with a study of the context in which they have arisen

allows us to reduce the disparity between long-term and short-term progression and development of kidney disease, as well as to improve patients' quality of life.

Acknowledgments

This article was made possible by funding from the Canary Islands Savings Bank (Caja de Canarias) and the Mapfre Guanarteme Foundation for the genetic and psychosocial study of patients with autosomal dominant polycystic kidney disease in the province of Las Palmas (Análisis Genético y Evaluación Psicosocial de pacientes con Poliquistosis Renal Autosómica Dominante en la Provincia de Las Palmas).

Conflicts of interest

The authors affirm that they have no conflicts of interest related to the content of this article.

1. Levenson J, Glocheski S. Psychological factors affecting end-stage renal

disease. *Psychosomatics* 1991; 32(4):382-9.

2. Nejastisafa AA. Prevalence of depression and anxiety in medical and surgical inpatients: a systematic review. *Iranian Journal of Psychiatry* 2007;2(4):181-5.
3. Kimmel PL, Peterson RA. Depression in end stage renal disease patients: Tools, correlates, outcomes and needs. *Semin Dial* 2005;18:91-7.
4. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361-70.
5. Drayer RA, Piraino B, Reynolds CF 3rd, Houck PR, Mazumdar S, Bernardini J, et al. Characteristics of depression in hemodialysis patients: symptoms quality of life and mortality risk. *Gen Hosp Psychiatry* 2006;28:306-12.
6. Kimmel PL, Peterson RA. Depression in patients with end stage renal disease treated with dialysis: Has the time to treat arrived? *Clin J Am Soc Nephrol* 2006;1:349-52.
7. Snaith RP. The Hospital Anxiety and Depression Scale. *Health Qual Life Outcomes* 2003;1:29.
8. Pérez-Domínguez TS, Rodríguez-Pérez A, Buset Ríos N, Rodríguez Esparragón F, García Bello MA, Pérez Borges P, et al. Avances en psiconefrolología: poliquistosis renal autosómica dominante y calidad de vida. *Nefrología* 2011;31(6): 716-22.
9. Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Validation of depression screening scales in patients with CKD. *Am J Kidney Dis* 2009;54(3):433-9.
10. Watnick S, Kirwin P, Mahnensmith R, Concato J. The prevalence and treatment of depression among patients starting dialysis. *Am J Kidney Dis* 2003;41(1):105-10.
11. Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S. Self-assessed physical and mental function of haemodialysis patients. *Nephrol Dial Transplant* 2001;16:1387-94.
12. Organización Mundial de la Salud. Manual de trastornos mentales y del comportamiento: descripciones clínicas y pautas para el diagnóstico. CIE 10. Ginebra (Suiza): Meditor; 1992.

Table 2. Mean score for each item on the hospital anxiety and depression questionnaire

| Anxiety items | HD | Non-HD | P |
|---|-------------|--------------|--------|
| Nervousness | 1.125±0.899 | 1.086±0.853 | 0.788 |
| Fear | 0.875±1.116 | 0.543±0.8168 | 0.058 |
| Concern | 1.123±1.116 | 1.029±1.071 | 0.811 |
| Ability to feel relaxed | 0.96±0.999 | 1±0.804 | 0.135 |
| Strange feeling in the pit of the stomach | 0.5±0.722 | 0.6±0.736 | 0.478 |
| Unrest | 1.125±1.154 | 0.688±0.758 | 0.006* |
| Depression items | HD | Non-HD | P |
| Capacity for enjoyment | 0.63±0.647 | 0.4±0.553 | 0.276 |
| Capacity for laughing | 0.25±0.505 | 0.26±0.442 | 0.766 |
| Happiness | 0.67±0.868 | 0.46±0.561 | 0.304 |
| Lethargy | 1.208±1.285 | 0.314±0.676 | 0.004* |
| Lost interest in appearance | 0.625±0.924 | 0.429±0.778 | 0.381 |
| Optimism for the future | 0.67±0.816 | 0.60±0.775 | 0.892 |
| Capacity for fun | 0.58±1.018 | 0.49±0.853 | 0.463 |

HD: haemodialysis patients; Non-HD: non-haemodialysis patients

* P<.05

Tais Pérez-Domínguez¹,
 Armando Rodríguez-Pérez²,
 Miguel A. García-Bello³, Nisa Buset-Ríos³,
 Francisco Rodríguez-Esparragón³,
 Yanet Parodis-López¹, José C. Rodríguez-Pérez¹,
 HIRICARE*

¹ Centro de Hemodiálisis RTS-Gran Canaria. Las Palmas de Gran Canaria. (Spain).

² Departamento de Psicología Social, Cognitiva y Organizacional. Universidad de La Laguna. La Laguna, Tenerife. (Spain).

³ Unidad de Investigación, Servicio de Nefrología. Hospital Universitario de Gran Canaria Dr. Negrín. Las Palmas de Gran Canaria. (Spain). ⁴ Servicio de Nefrología y Unidad de Investigación. Hospital Universitario de Gran Canaria Dr. Negrín, Universidad de Las Palmas de Gran Canaria. Las Palmas de Gran Canaria. (Spain).

* Unidad de Investigación, Servicio de Nefrología. Hospital Universitario de Gran Canaria Dr. Negrín. Las Palmas de Gran Canaria. (Spain).

***Group members:** Dña. Arantza Anabitarte Prieto, Dña. Cristina García Laverick, Dra. Carmen Rosa Hernández Socorro, Dr. Luis Hortal Cascón, Dra. Elena Oliva Dámaso, Dra. Yanet Parodis López, Dra. Patricia Pérez Borges, Dra. Nery Sablón González, Dña. Raquel Talavera García.

Correspondence: José C. Rodríguez Pérez
 Servicio de Nefrología y Unidad de Investigación,
 Hospital Universitario de Gran Canaria
 Dr. Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria. (Spain).
 jrodperd@gobiernodecanarias.org

Diabetic foot and renal failure. Theoretical and practical considerations

Nefrología 2012;32(3):399

doi:10.3265/Nefrologia.pre2012.Feb.11385

To the Editor,

Diabetic patients with diabetic foot have high mortality rates and it has been suggested that aggressive cardiovascular treatment decreases morbidity and mor-

tality in these patients.^{1,2} As such, we decided to perform a retrospective review of the level of compliance with consensus documents on secondary prevention in patients with diabetic foot at their first hospital examination. We assessed a total of 129 patients, collecting clinical information, haemogram and biochemical test results, and treatments administered. We performed all statistical analyses using SPSS statistical software version 15.0. Of the 129 patients studied, 80 were male and 49 were female, with a mean age of 63.02±13.49 years. The clinical parameters measured revealed arterial hypertension in 71.3% of patients, 23.3% were active smokers, mean HbA_{1c} was 8.74±2.23%, mean LDL cholesterol was 90.06±35.58mg/dl, and mean triglycerides were 151.84±82.49mg/dl. As regards treatment, 64.3% received insulin and 43.4% oral anti-diabetic drugs. In addition, 52.7% of patients received statins, 1.6% fibrates, 13.2% allopurinol, 21.7% calcium antagonists, 38.8% diuretics, 14.7% beta blockers, 24.8% angiotensin-converting enzyme (ACE) inhibitors, 30.2% angiotensin receptor blockers (ARB), and 55.8% anti-platelet drugs. Thirty-one patients (24%) had a MDRD-4<60ml/min. As compared to patients with an MDRD-4>60ml/min, this group was older (70.52±10.87 years vs 60.04±12.64 years; *P*=.000), had lower levels of Hb (10.62±1.79g/dl vs 12.33±1.96g/dl; *P*=.000) and haematocrit (31.71±5.77% vs 36.04±5.46%; *P*=.001), and had higher levels of K⁺ (4.77±0.56mmol/l vs 4.52±0.39mmol/l; *P*=.027), uric acid (6.86±2.16mg/dl vs 4.67±1.18mg/dl; *P*=.000), and red blood cell distribution width (RDW) (16.93±3.75% vs 14.16±2.53%; *P*=.000), with no differences based on the treatments administered. Based on these results, we can conclude that patients with diabetic foot that seek their first hospital evaluation have hypertension, poorly controlled high glucose levels, and are receiving treatments that are quite different from those recommended for secondary prevention. We must point out that approximately 20% of patients in our study also had chronic renal failure, and there were no significant differences in terms of treatment administered be-

tween this sub-group and all other patients. Furthermore, these patients with diabetic foot and chronic renal failure had a higher percentage of RDW, which has been associated with increased mortality.³

In order to achieve treatment targets and a change in mentality, it is important to know the present situation and prioritise the goals accordingly. The fact that 44.2% of these patients go without anti-platelet treatment, 35% without ACE inhibitors or ARBs, and 47.3% without statin treatment should lead us to reflect upon the current reality and how to bring our clinical action more in line with theoretical recommendations on a long-term basis.

Conflicts of interest

The authors affirm that they have no conflicts of interest related to the content of this article.

1. Rathur H, Rajbhandari SM. Prevention of diabetic foot ulcers: Holy grail of foot clinics. *Int J Diabetes & Metabolism* 2003;11:56-61.
2. American Diabetes Association. Standards of Medical Care in Diabetes-2011. *Diabetes Care* 2011;34(Suppl 1):S11-S61.
3. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM. Red blood cell distribution width and the risk of death in middle-aged and older adults. *Arch Intern Med* 2009;169(5):513-23.

Fátima Batista-García¹, Michele Hernández²,
 Santiago Suria¹, Noemí Esparza¹,
 M. Dolores Checa¹

¹ Servicio de Nefrología. Hospital Universitario Insular de Gran Canaria. Las Palmas de Gran Canaria. (Spain).

² Unidad de Pie Diabético. Unidad de Enfermedades Infecciosas y Medicina Tropical. Hospital Universitario Insular de Gran Canaria. Las Palmas de Gran Canaria. (Spain).

Correspondence: Noemí Esparza

Servicio de Nefrología.
 Hospital Universitario Insular de Gran Canaria.
 Avenida Marítima del Sur s/n.
 35260 Las Palmas de Gran Canaria. (Spain).
 noemiesparza@telefonica.net